Clinical Trials Logo

Opioid Intoxication clinical trials

View clinical trials related to Opioid Intoxication.

Filter by:
  • None
  • Page 1

NCT ID: NCT04047550 Completed - Clinical trials for Ventilatory Depression

Respiratory Control and Narcotic Effects

Start date: March 8, 2018
Phase:
Study type: Observational

The aim of this study is to provide data that will assess the role of ventilatory chemosensitivity (respiratory drive) in determining postoperative respiratory depression due to opioids. In a group of patients requiring surgery and admission to hospital, before surgery, ventilatory chemosensitivity will be assessed in the presence or absence of an infusion of remifentanil. Parameters will be correlated with ventilatory depression events after surgery. A secondary aim is to determine whether respiratory depression is more likely during specific phases of sleep.

NCT ID: NCT03879460 Completed - Opioid Intoxication Clinical Trials

The Evaluation of Safety and Tolerance of Commercially Available Naltrexone Administered Daily - Assessment for CBRN Operations

TEST CANADA
Start date: March 18, 2019
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate the tolerance and safety of naltrexone while performing military specific tasks, and to assess plasma concentrations following naltrexone, administered orally at 50 mg per day for 7 days. The physical and mental/cognitive performance assessments will be conducted at various times prior, during and following drug administration. Daily blood draws will also be taken to assess blood levels of naltrexone and active metabolites for correlation to performance parameters associated with the Military Skill & Tasked Based Fitness Test.

NCT ID: NCT03394911 Not yet recruiting - Opioid Use Clinical Trials

Healthy Adult Male Facial Skin Surface Lipid Pheromone p.o. to Treat Opioid Addiction

Start date: December 31, 2020
Phase: Phase 3
Study type: Interventional

Healthy adult human male facial skin surface lipid liquid pheromone given by mouth to opioid addicts cures them without any withdrawal symptoms whatsoever 250mg on chewing gum vehicle by mouth. Elevated mood eventually becomes accommodated after a few weeks. The pheromone contains volatile airborne sub-pheromones which cause aversive behavior (distrust, superstition, suspicion, arrogance, astonishment/stupidity, jealousy). Artificial jealousy can be avoided by patient isolation for 40 days until the pheromone "taste" wears off the saliva. The pheromone provided is odorless, colorless, and tasteless to the conscious brain.

NCT ID: NCT03368794 Withdrawn - Clinical trials for Substance Use Disorders

Naloxone to TReatment Entry in the Emergency Setting

N-TREE
Start date: September 15, 2017
Phase: N/A
Study type: Interventional

The study tests a structured referral process for opioid overdose survivors, from pre-hospital emergency care to long-term treatment of the individual's substance use-related disorder.